within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX77_Adagrasib;

model Adagrasib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.34,
    Cl = 7.444444444444445e-06,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.167,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006666666666666667,
    Tlag = 12.6,
    Vdp = 0.149,
    k12 = 3.194444444444445e-05,
    k21 = 3.194444444444445e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Adagrasib</td></tr><tr><td>ATC code:</td><td>L01XX77</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>167</td><td>L</td></tr>
    <tr><td>clearance:</td><td>26.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Adagrasib is an orally active, irreversible KRAS G12C inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation. It is approved for medical use for this indication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult patients with advanced solid tumors (predominantly NSCLC), both sexes, median age ~65 years.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XX77 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Adagrasib;
